Advertisement
Screener

Beam Therapeutics Inc. (BEAM) EBITDA

Beam Therapeutics Inc. (BEAM) EBITDA

  • 2026-06-30: Basis Reported; EBITDA -$121.14M*; Operating income -$126.55M; Depreciation and amortization $5.41M*.
  • 2026-03-31: Basis Reported; EBITDA -$101.61M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$11.78M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA -$121.25M*; Operating income -$126.81M; Depreciation and amortization $5.56M*.

Complete source-backed ebitda history.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported-$121.14M*-$126.55M$5.41M*$490.00K-24723.06%*$2.41M*-$66.10M*(m)$95.10M(m)$0.00*
2026-03-31Reported-$101.61M(m)(m)(m)-320.15%$2.23M-$128.51M(m)$104.52M(m)$0.00
2025-12-31Reported-$11.78M(m)(m)(m)-10.32%(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$121.25M*-$126.81M$5.56M*$9.70M-1250.27%*$5.01M*-$81.48M*(m)$109.77M(m)$0.00*
2025-06-30Reported-$114.61M*-$120.15M$5.54M*$8.47M-1353.80%*$3.14M*-$76.45M*(m)$101.76M(m)$0.00*
2025-03-31Reported-$113.76M(m)(m)(m)-1522.86%$3.06M-$103.88M(m)$98.82M(m)$0.00
2024-12-31Reported-$94.59M(m)(m)(m)-314.61%(m)(m)(m)(m)(m)(m)
2024-09-30Reported-$101.03M*-$106.50M$5.47M*$14.27M-708.03%*$1.58M*-$88.13M*(m)$94.26M(m)$0.00*
2024-06-30Reported-$99.32M*-$104.89M$5.58M*$11.77M-843.69%*$1.96M*-$83.01M*(m)$87.04M(m)$39.00K
2024-03-31Reported-$98.7M(m)(m)(m)-1332.00%$2.44M-$99.75M(m)$84.82M(m)$0.00
2023-12-31Reported$138.22M(m)(m)(m)43.71%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$103.08M*-$108.27M$5.19M*$17.19M-599.55%*$7.95M*-$89.78M*(m)$100.05M(m)$0.00
2023-06-30Reported-$97.33M*-$102.15M$4.82M*$20.12M-483.85%*$16.18M*-$84.67M*(m)$97.61M(m)$0.00
2023-03-31Reported-$94.28M(m)(m)(m)-389.46%$6.02M-$109.81M(m)$99.65M(m)$0.00
2022-12-31Reported-$85.04M(m)(m)(m)-424.42%(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$87.83M*-$91.30M$3.47M*$15.80M-555.92%*$11.79M*-$74.50M*(m)$85.29M(m)$2.41M
2022-06-30Reported-$78.55M*-$81.97M$3.42M*$16.65M-471.70%*$21.64M*-$52.28M*(m)$74.56M(m)$0.00
2022-03-31Reported-$72.91M(m)(m)(m)-864.72%$7.26M$218.49M(m)$65.41M(m)$0.00
2021-12-31Reported-$60.85M(m)(m)(m)-119.15%(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$67.88M*-$69.63M$1.75M*$763.00K-8896.99%*$5.78M*$3.01M*(m)$54.62M(m)$0.00
2021-06-30Reported-$57.30M*-$58.97M$1.67M*$6.00K-955083.33%*$16.18M*-$32.53M*(m)$45.58M(m)(m)
2021-03-31Reported-$198.98M(m)(m)(m)-3316250.00%$11.48M-$38.58M(m)$190.11M(m)(m)
2020-12-31Reported-$39.53M(m)(m)(m)-658783.33%(m)(m)(m)(m)(m)(m)
2020-09-30Reported-$36.10M*-$37.32M$1.22M*$6.00K-601716.67%*$2.82M*-$21.21M*(m)$29.82M(m)(m)
2020-06-30Reported-$25.14M*-$26.29M$1.15M*$6.00K-419000.00%*$2.37M*-$22.84M*(m)$19.35M(m)(m)
2020-03-31Reported-$27.26M(m)(m)(m)-454250.00%$3.05M-$27.39M(m)$21.55M(m)(m)
2019-09-30Reported(m)-$18.02M(m)(m)(m)$1.42M*-$16.99M*(m)$12.54M(m)(m)
2019-06-30Reported(m)-$17.65M(m)(m)(m)$6.58M*-$11.35M*(m)$12.68M(m)(m)
2019-03-31Reported(m)-$13.11M(m)(m)(m)$2.35M-$25.86M(m)$9.18M(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$361.4M(m)(m)(m)-258.62%$14.95M-$345.10M(m)$409.62M(m)$0.00
2024-12-31Reported-$393.64M(m)(m)(m)-619.73%$8.95M-$347.25M(m)$367.56M(m)$39.00K
2023-12-31Reported-$156.47M(m)(m)(m)-41.43%$33.73M-$149.19M(m)$437.38M(m)$1.37M
2022-12-31Reported-$324.33M(m)(m)(m)-532.39%$48.95M$22.53M(m)$311.59M(m)$3.41M
2021-12-31Reported-$385.01M(m)(m)(m)-742.64%$46.81M-$66.27M(m)$387.09M(m)$0.00
2020-12-31Reported-$128.03M(m)(m)(m)-533437.50%$16.36M-$95.74M(m)$103.18M(m)$0.00
2019-12-31Reported-$71.65M(m)(m)(m)-398061.11%$12.52M-$72.00M(m)$54.62M(m)$0.00

Similar stocks

Stock NameCountryMarket CapPE Ratio
Greenland Mines Ltd (GRML)United States$2.362B
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Vericel Corp (VCEL)United States$2.011B93.97
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
NOVAVAX INC (NVAX)United States$1.748B-6.26